PLD3 gene variants and Alzheimer's disease

Nature

Volumn 520, Issue 7545, 2015, Pages E7-E8

  Hooli, Basavaraj V ^a   Lill, Christina M ^b,c,d   Mullin, Kristina ^a   Qiao, Dandi ^e   Lange, Christoph ^e   Bertram, Lars ^b,d,f   Tanzi, Rudolph E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; METHIONINE; PHOSPHOLIPASE; PHOSPHOLIPASE D3; UNCLASSIFIED DRUG; PHOSPHOLIPASE D;

DISEASE INCIDENCE; DNA; GENE EXPRESSION; GENETIC ANALYSIS;

AGED; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ARTICLE; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CONTROLLED STUDY; FAMILY; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); ONSET AGE; PRIORITY JOURNAL; RISK FACTOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE;

ALZHEIMER DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; PHOSPHOLIPASE D;

EID: 84926293839     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14040     Document Type: Article

References (11)

1. Cruchaga, C. et al. Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature 505, 550-554 (2014).
2. Heilmann, S. et al. PLD3 in non-familial Alzheimer's disease. Nature 520, http://dx.doi.org/10.1038/nature14039 (2015).
3. Lambert, J.-C. et al. PLD3 and sporadic Alzheimer's disease risk. Nature 520, http://dx.doi.org/10.1038/nature14036 (2015).
4. van der Lee, S. J. et al. PLD3 variants in population studies. Nature 520, http://dx.doi.org/10.1038/nature14038 (2015).
5. Lambert, J. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genet. 45, 1452-1458 (2013).
6. Blacker, D. et al. Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum. Mol. Genet. 12, 23-32 (2003).
7. De, G., Yip, W. K., Ionita-Laza, I. & Laird, N. Rare variant analysis for family-based design. PLoS ONE 8, e48495 (2013).
8. Cantarel, B. L. et al. BAYSIC: a Bayesian method for combining sets of genome variants with improved specificity and sensitivity. BMC Bioinform. 15, 104 (2014).
9. Laird, N. M., Horvath, S. & Xu, X. Implementing a unified approach to family-based tests of association. Genet. Epidemiol. 19 (suppl. 1), S36-S42 (2000).
10. Won, S. et al. On the analysis of genome-wide association studies in family-based designs: a universal, robust analysis approach and an application to four genome-wide association studies. PLoS Genet. 5, e1000741 (2009).
11. Lill, C. M. et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet. 8, e1002548 (2012).